Ocular biocompatibility of dexamethasone acetate loaded poly(ɛ-caprolactone) nanofibers

Silva, Gisele Rodrigues da; Lima, Tadeu Henrique; Fernandes-Cunha, Gabriella; Oréfice, Rodrigo Lambert; Silva-Cunha, Armando; Zhao, Min; Béhar-Cohen, Francine

doi:10.1016/j.ejpb.2019.05.010

Cited by 38 publications

(18 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such examples have been reported in literature using poly(ethylene glycol) (PEG) with zinc ion bridging [ 118 ] for DexSP nanoencapsulation and PLGA microspheres [ 119 , 120 ] where DexSP was released up to 25 and 30 days, respectively. Similar extended release profiles of Dex have been reported for intracanalicular applications (up to 30 days) [ 121 ] and up to 12 days from poly(ɛ-caprolactone) nanofibers [ 122 ]. However, these polymers have low mucoadhesion and thus cannot be used in drop eyes solutions.…”

Section: Resultssupporting

confidence: 75%

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

et al. 2020

View full text Add to dashboard Cite

The aim of this work was to evaluate the effectiveness of neat chitosan (CS) and its derivatives with 2-acrylamido-2-methyl-1-propanesulfonic acid (AAMPS) and [2-(methacryloyloxy)ethyl]dimethyl-(3-sulfopropyl)ammonium hydroxide (MEDSP) as appropriate nanocarriers for the simultaneous ocular administration of dexamethasone sodium phosphate (DxP) and chloramphenicol (CHL). The derivatives CS-AAMPS and CS-MEDSP have been synthesized by free-radical polymerization and their structure has been proved by Fourier-Transformed Infrared Spectroscopy (FT-IR) spectroscopy. Both derivatives exhibited low cytotoxicity, enhanced mucoadhesive properties and antimicrobial activity against Staphylococcus aureus (S.aureus) and Escherichia coli (E. coli). Encapsulation was performed via ionic crosslinking gelation using sodium tripolyphosphate (TPP) as the crosslinking agent. Dynamic light scattering measurements (DLS) showed that the prepared nanoparticles had bimodal distribution and sizes ranging from 50–200 nm and 300–800 nm. Drugs were encapsulated in their crystalline (CHL) or amorphous (DexSP) form inside nanoparticles and their release rate was dependent on the used polymer. The CHL dissolution rate was substantially enhanced compared to the neat drug and the release time was extended up to 7 days. The release rate of DexSP was much faster than that of CHL and was prolonged up to 3 days. Drug release modeling unveiled that diffusion is the main release mechanism for both drugs. Both prepared derivatives and their drug-loaded nanoparticles could be used for extended and simultaneous ocular release formulations of DexSP and CHL drugs.

show abstract

Section: Resultssupporting

confidence: 75%

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Since nanotechnology has received a great deal of attention in recent years, nanofibers are expected to become an integral part of frequently used dosage forms in the near future, as they are able to penetrate and target different sites, including posterior segments of the eye [ 38 ] and the vitreous cavity for the treatment of retinal diseases [ 99 ]. From a technical point of view, nanofibers can be used directly as films [ 58 ] or after further processing into suitable ocular inserts or other surface modifications [ 100 ].…”

Section: Future Perspectivementioning

confidence: 99%

A Systematic Review of Drug-Loaded Electrospun Nanofiber-Based Ophthalmic Inserts

Omer

Zelkó

2021

Pharmaceutics

View full text Add to dashboard Cite

Currently, ocular inserts and nanoparticles have received much attention due to the limited bioavailability of conventional eye preparations and the toxicity problems of systemic drug administration. The current systematic review aims to present recent studies on the use of electrospun nanofiber-based ocular inserts to improve the bioavailability of drugs used for different ophthalmic diseases. A systematic search was performed in PubMed, Ovid Medline, Web of Science, ScienceDirect, Scopus, Reaxys, Google Scholar, and Google Patents/Espacenet taking “drug-loaded”, “nanofibers”, and “ophthalmic inserts” and their equivalent terms as keywords. The search was limited to original and peer-reviewed studies published in 2011–2021 in English language. Only 13 out of 795 articles and 15 out of 197 patents were included. All results revealed the success of nanofiber-based ocular inserts in targeting and improved bioavailability. Ocular inserts based on nanofibers can be used as safe, efficient carriers for the treatment of anterior and posterior eye diseases.

show abstract

“…The antimicrobial activity comprises various mechanisms, such as intercellular reactions, changes in bacterial membrane permeability, interferences with the synthesis of bacterial cell protein and induction of the aggregation of bacterial proteins [36]. In the ocular field, electrospun nanofibers are gaining interest as soft materials that can easily adapt to cornea and sclera surfaces and remain on the eye surface for a moderate period of time acting as sustained release platforms [13][14][15]. Thus, compared to liquid and semisolid formulations, electrospun inserts may overcome better the precorneal barriers that oppose to ocular bioavailability after topical application [16].…”

Section: Introductionmentioning

confidence: 99%

Crosslinked Hyaluronan Electrospun Nanofibers for Ferulic Acid Ocular Delivery

Grimaudo

Concheiro

2020

Pharmaceutics

View full text Add to dashboard Cite

Electrospun nanofibers are gaining interest as ocular drug delivery platforms that may adapt to the eye surface and provide sustained release. The aim of this work was to design an innovative ophthalmic insert composed of hyaluronan (HA) nanofibers for the dual delivery of an antioxidant (ferulic acid, FA) and an antimicrobial peptide (ε-polylysine, ε-PL). Polyvinylpyrrolidone (PVP) was added to facilitate the electrospinning process. Fibers with diameters of approx. 100 nm were obtained with PVP 5%-HA 0.8% w/v and PVP 10%-HA 0.5% w/v mixtures in ethanol:water 4:6 v/v. An increase in PVP concentration to 20% w/v in both presence and absence of HA rendered fibers of approx. 1 µm. PVP 5%-HA 0.8% w/v fibers were loaded with 83.3 ± 14.0 µg FA per mg. After nanofibers crosslinking with ε-PL, blank and FA-loaded inserts showed a mean thickness of 270 ± 21 µm and 273 ± 41 µm, respectively. Blank and FA-loaded inserts completely released ε-PL within 30 min under sink conditions, whereas FA-loaded inserts released the antioxidant within 20 min. Both blank and FA-loaded inserts were challenged against Pseudomonas aeruginosa and Staphylococcus aureus, demonstrating their efficacy against relevant microbial species.

show abstract

Ocular biocompatibility of dexamethasone acetate loaded poly(ɛ-caprolactone) nanofibers

Cited by 38 publications

References 32 publications

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

Chitosan Derivatives with Mucoadhesive and Antimicrobial Properties for Simultaneous Nanoencapsulation and Extended Ocular Release Formulations of Dexamethasone and Chloramphenicol Drugs

A Systematic Review of Drug-Loaded Electrospun Nanofiber-Based Ophthalmic Inserts

Crosslinked Hyaluronan Electrospun Nanofibers for Ferulic Acid Ocular Delivery

Contact Info

Product

Resources

About